Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging subcutaneous Phleum pratense immunotherapy study in allergic rhinoconjunctivitis
2011-000814-21Phase 2Completed
- Sponsor
- BIAL
- Start
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allergovac depot in allergic rhinoconjunctivitis (ARC) and allergic asthma (6 arms), sponsored by BIAL. Primary endpoint: Change in nasal provocation threshold. Started Jun 2011; status: completed.
02
Drugs
allergovac depot
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2011-000814-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000814-21.